Journal article

Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk

Dalia H Ghoneim, Jingjing Zhu, Wei Zheng, Jirong Long, Harvey J Murff, Fei Ye, Veronica Wendy Setiawan, Lynne R Wilkens, Nikhil K Khankari, Philip Haycock, Samuel O Antwi, Yaohua Yang, Alan A Arslan, Laura E Beane Freeman, Paige M Bracci, Federico Canzian, Mengmeng Du, Steven Gallinger, Graham G Giles, Phyllis J Goodman Show all

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | AMER ASSOC CANCER RESEARCH | Published : 2020

Abstract

BACKGROUND: Whether circulating polyunsaturated fatty acid (PUFA) levels are associated with pancreatic cancer risk is uncertain. Mendelian randomization (MR) represents a study design using genetic instruments to better characterize the relationship between exposure and outcome. METHODS: We utilized data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case-Control Consortium, involving approximately 9,269 cases and 12,530 controls of European descent, to evaluate associations between pancreatic cancer risk and genetically predicted plasma n-6 PUFA levels. Conventional MR analyses were performed using individual-level and summary-leve..

View full abstract

Grants

Awarded by NCI


Awarded by National Heart, Lung, and Blood Institute, NIH, and U.S. Department of Health and Human Services


Awarded by NCI-NIH



Funding Acknowledgements

The authors are indebted to the research team and participants of the PanScan and PanC4 consortia participating studies for their contributions to this study. This study was supported by NCI grants K99 CA218892 and R00 CA218892. The Multiethnic Cohort was supported by grant U01 CA164973. The Women's Health Initiative program was funded by the National Heart, Lung, and Blood Institute, NIH, and U.S. Department of Health and Human Services through contractsHHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The Connecticut Pancreas Cancer Study was supported, in part, by NCI-NIH grant 5R01CA098870 (to H.A. Risch). The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. This study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in this study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. A detailed list of acknowledgments for other PanScan/PanC4 participating studies is included elsewhere (Klein and colleagues; ref. 7).